ELOXX

eloxx-logo

Eloxx Pharmaceuticals based in Israel is a Pontifax portfolio company established in 2013 by Dr. Silvia Noiman, that serves as its Executive Chairman and Dr. Shmuel Tuvia. The company, is a biopharmaceutical company focused on discovery, development and commercialization of compounds for the treatment of genetic diseases caused by nonsense mutations including: Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, Tay-Sachs Hurler syndrome and many ... others. Eloxx Pharmaceuticals approach and knowhow allows moving rapidly from target drugs discovery program to clinical drug candidates. Building a robust pipeline of molecules designed for an array of nonsense genetic diseases. Translation of mRNA to a protein is the event where the cellular machinery, i.e. ribosome, ultimately dictates the quantity and timing for each protein to be produced. Thus, molecules that induce ribosomal readthrough overcome the nonsense mutations and allow production of a full-length functional protein. These molecules hold great therapeutic potential for the treatment of many genetic diseases.

#SimilarOrganizations #People #Financial #Event #Website #More

ELOXX

Social Links:

Industry:
Biotechnology Genetics Health Care

Founded:
2013-01-01

Address:
Waltham, Massachusetts, United States

Country:
United States

Website Url:
http://www.eloxxpharma.com

Total Employee:
11+

Status:
Active

Contact:
+1-781-577-5300

Email Addresses:
info@eloxxpharma.com

Total Funding:
92.39 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics


Similar Organizations

aimmune-therapeutics-logo

Aimmune Therapeutics

Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.

edgewise-therapeutics-logo

Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.


Current Advisors List

martijn-kleijwegt_image

Martijn Kleijwegt Board of Director @ Eloxx
Board_member

silvia-noiman_image

Silvia Noiman Board Member @ Eloxx
Board_member

Current Employees Featured

not_available_image

Vijay Modur
Vijay Modur Head of Research and Development @ Eloxx
Head of Research and Development
2021-04-01

greg-williams_image

Greg Williams
Greg Williams Chief Operating Officer @ Eloxx
Chief Operating Officer

not_available_image

Ali Hariri
Ali Hariri Chief Medical Officer @ Eloxx
Chief Medical Officer
2021-09-01

gregory-weaver_image

Gregory Weaver
Gregory Weaver Chief Financial Officer @ Eloxx
Chief Financial Officer
2017-09-01

robert-e-ward_image

Robert E. Ward
Robert E. Ward Chairman and Chief Executive Officer @ Eloxx
Chairman and Chief Executive Officer
2017-12-01

silvia-noiman_image

Silvia Noiman
Silvia Noiman Founder @ Eloxx
Founder

Founder


silvia-noiman_image

Silvia Noiman

Stock Details


Company's stock symbol is NASDAQ:ELOX

Acquisitions List

Date Company Article Price
2021-04-01 Zikani Therapeutics Zikani Therapeutics acquired by Eloxx N/A
2017-06-03 Sevion Therapeutics Sevion Therapeutics acquired by Eloxx N/A

Investors List

the-cystic-fibrosis-foundation_image

Cystic Fibrosis Foundation

Cystic Fibrosis Foundation investment in Grant - Eloxx

herculescapital_image

Hercules Capital

Hercules Capital investment in Post-IPO Debt - Eloxx

the-cystic-fibrosis-foundation_image

Cystic Fibrosis Foundation

Cystic Fibrosis Foundation investment in Grant - Eloxx

the-cystic-fibrosis-foundation_image

Cystic Fibrosis Foundation

Cystic Fibrosis Foundation investment in Grant - Eloxx

the-cystic-fibrosis-foundation_image

Cystic Fibrosis Foundation

Cystic Fibrosis Foundation investment in Grant - Eloxx

cybele-holdings_image

Cybele Holdings

Cybele Holdings investment in Venture Round - Eloxx

korea-investment-partners_image

Korea Investment Partners

Korea Investment Partners investment in Series C - Eloxx

quark-venture_image

Quark Venture

Quark Venture investment in Series C - Eloxx

pontifax_image

Pontifax

Pontifax investment in Series C - Eloxx

lsp-bioventures_image

LSP BioVentures

LSP BioVentures investment in Series C - Eloxx

Official Site Inspections

http://www.eloxxpharma.com Semrush global rank: 9.48 M Semrush visits lastest month: 150

  • Host name: 208.66.66.34.bc.googleusercontent.com
  • IP address: 34.66.66.208
  • Location: United States
  • Latitude: 38.6583
  • Longitude: -77.2481
  • Timezone: America/New_York

Eloxxpharma.com lookup results from whois.fastdomain.com server:
  • Domain created: 13th-Oct-2013
  • Domain updated: 28th-Sep-2024
  • Domain expires: 13th-Oct-2025 0 Years, 274 Days left
  • Website age: 11 Years, 91 Days
  • Registrar Domain ID: 1830930096_DOMAIN_COM-VRSN
  • Registrar Url: http://www.fastdomain.com
  • Registrar WHOIS Server: whois.fastdomain.com
  • Registrar Abuse Contact Email: domain.operations@web.com
  • Registrar Abuse Contact Phone: +1.8777228662
  • Name server:
    • NS1.BLUEHOST.COM
    • NS2.BLUEHOST.COM

More informations about "Eloxx"

About Us - Eloxx Pharmaceuticals

She is founder, president and CEO of Roivant Social Ventures, a social impact organization that makes early-stage investments and incubates biotech companies focused on improving healthcare access and outcomes for …See details»

Company - Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates are designed to be eukaryotic ribosomal selective glycosides …See details»

Home - Eloxx Pharmaceuticals

Our platform technologies are uniquely positioned to transform genetic diseases by correcting two defects, nonsense mutations implicated in many rare diseases and ribosomal mutations …See details»

Eloxx Pharmaceuticals, Inc. - Drug pipelines, Patents, Clinical trials ...

Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in Phase 2 clinical …See details»

Eloxx - Crunchbase Company Profile & Funding

Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates.See details»

Eloxx Pharmaceuticals, Inc. (ELOX) - Yahoo Finance

See the company profile for Eloxx Pharmaceuticals, Inc. (ELOX) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»

Eloxx Pharmaceuticals CEO and Key Executive Team | Craft.co

Eloxx Pharmaceuticals's President, Chief Executive Officer and Board Member is Sumit Aggarwal. Other executives include Ali Hariri, Chief Medical Officer; Daniel Geffken, Interim …See details»

Eloxx Pharmaceuticals - ZoomInfo

Mar 12, 2024 View Eloxx Pharmaceuticals (www.eloxxpharma.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar companies as well …See details»

Eloxx Pharmaceuticals - LinkedIn

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon ...See details»

Eloxx Pharmaceuticals Company Description - Stock Analysis

Nov 13, 2024 Company profile for Eloxx Pharmaceuticals, Inc. (ELOX) with a description, list of executives, contact details and other key facts.See details»

Eloxx Pharma - EQT Group

Latest news 29 November 2024 EQT Exeter completes Spanish student housing portfolio sale to Azora 26 November 2024 EQT portfolio company Parcel2Go announces new ownership 22 …See details»

ELOXX PHARMACEUTICALS INC CORPORATE GOVERNANCE …

The basic responsibility of the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) is to exercise its business judgment to act in a manner that each director …See details»

Eloxx Pharmaceuticals - Craft

Sep 30, 2024 Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovery, development, and commercialization of compounds for the treatment of genetic …See details»

Eloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual ...

WATERTOWN, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, …See details»

Eloxx Pharmaceuticals Announces Changes to Board of

Jul 5, 2022 Ms. Androski, JD, MBA is founder, President and CEO of Roivant Social Ventures, a social impact organization that makes early stage investments and incubates biotech …See details»

Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

Nov 12, 2024 Data from Eloxx’s proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American Society of Nephrology …See details»

Contact Us - Eloxx Pharmaceuticals

Reach us by email or by calling our corporate headquarters.See details»

Careers and - Eloxx Pharmaceuticals

Join our team If you would like to be part of our rapidly growing, entrepreneurial culture that promotes diversity, operates through strong teamwork and collaboration, and rewards …See details»

Eloxx Pharmaceuticals Acquires Zikani Therapeutics - Yahoo Finance

Eloxx is headquartered in Waltham, MA, with operations in Rehovot, Israel, and Morristown, NJ. For more information, please visit www.eloxxpharma.com.See details»

Eloxx Pharmaceuticals (ELOX) Stock Price, News & Analysis

2 days ago Should You Buy or Sell Eloxx Pharmaceuticals Stock? Get The Latest ELOX Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat.See details»

linkstock.net © 2022. All rights reserved